PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmjcredLink to Publisher's site
 
Br Med J (Clin Res Ed). 1988 April 30; 296(6631): 1217–1220.
PMCID: PMC2545702

Weight loss in obese subjects on a restricted diet given BRL 26830A, a new atypical β adrenoceptor agonist

Abstract

A double blind placebo controlled study was carried out in 40 subjects newly referred for treatment for obesity to determine the effects of the new thermogenic β adrenoceptor agonist BRL 26830A. The subjects were randomised to receive either BRL 26830A, 200 mg daily for two weeks then 400 mg daily, or placebo for 18 weeks, and all were instructed to follow a 3·35 MJ diet that was low in fat and high in fibre. Weight loss was 15·4 (SD 6·6) kg in subjects given BRL 26830A compared with 10·0 (5·9) kg in those given placebo (p=0·02). The relative weight loss was 0·93 (0·39)% a week with BRL 26830A and 0·61 (0·38)% with placebo (p=0·02). Urinary excretion of nitrogen was similar in both groups, whereas measurements of skinfold thickness indicated a 4·1 kg difference in the amount of fat lost, suggesting that weight loss with BRL 26830A was mainly from adipose and not lean tissue. BRL 26830A had no effect on resting pulse rate or pressor effects on either diastolic or systolic blood pressure. No significant differences were found between the two groups in serum cholesterol concentration, percentage of high density lipoprotein cholesterol, plasma concentrations of glucose and insulin, the ratio of glucose to insulin, serum concentrations of triiodothyronine and thyroxine, and creatinine clearance. Short term administration of BRL 26830A to six subjects who had taken the drug for 18 weeks showed that the expenditure of energy increased by 11·6% during the second hour after administration, which suggests that BRL 26830A may enhance weight loss thermogenically.

BRL 26830A may be a useful drug in the treatment of obesity.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (950K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Arch JR, Ainsworth AT. Thermogenic and antiobesity activity of a novel beta-adrenoceptor agonist (BRL 26830A) in mice and rats. Am J Clin Nutr. 1983 Oct;38(4):549–558. [PubMed]
  • Arch JR, Ainsworth AT, Cawthorne MA, Piercy V, Sennitt MV, Thody VE, Wilson C, Wilson S. Atypical beta-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature. 1984 May 10;309(5964):163–165. [PubMed]
  • Arch JR, Ainsworth AT, Ellis RD, Piercy V, Thody VE, Thurlby PL, Wilson C, Wilson S, Young P. Treatment of obesity with thermogenic beta-adrenoceptor agonists: studies on BRL 26830A in rodents. Int J Obes. 1984;8 (Suppl 1):1–11. [PubMed]
  • Thurlby PL, Ellis RD. Differences between the effects of noradrenaline and the beta-adrenoceptor agonist BRL 28410 in brown adipose tissue and hind limb of the anaesthetized rat. Can J Physiol Pharmacol. 1986 Aug;64(8):1111–1114. [PubMed]
  • WEIR JBDEB. New methods for calculating metabolic rate with special reference to protein metabolism. J Physiol. 1949 Aug;109(1-2):1–9. [PubMed]
  • Jung RT, Shetty PS, James WP, Barrand MA, Callingham BA. Reduced thermogenesis in obesity. Nature. 1979 May 24;279(5711):322–323. [PubMed]
  • Roberts I, Smith IM. A simple method for the measurement of glycerol in serum. Ann Clin Biochem. 1986 Jul;23(Pt 4):490–491. [PubMed]
  • Durnin JV, Womersley J. Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years. Br J Nutr. 1974 Jul;32(1):77–97. [PubMed]
  • Galloway SM, Farquhar DL, Munro JF. The current status of antiobesity drugs. Postgrad Med J. 1984;60 (Suppl 3):19–26. [PubMed]
  • Stunkard AJ, Craighead LW, O'Brien R. Controlled trial of behaviour therapy, pharmacotherapy, and their combination in the treatment of obesity. Lancet. 1980 Nov 15;2(8203):1045–1047. [PubMed]
  • Kyle LH, Ball MF, Doolan PD. Effect of thyroid hormone on body composition in myxedema and obesity. N Engl J Med. 1966 Jul 7;275(1):12–17. [PubMed]
  • Bray GA, Melvin KE, Chopra IJ. Effect of triiodothyronine on some metabolic responses of obese patients. Am J Clin Nutr. 1973 Jul;26(7):715–721. [PubMed]
  • Astrup A, Lundsgaard C, Madsen J, Christensen NJ. Enhanced thermogenic responsiveness during chronic ephedrine treatment in man. Am J Clin Nutr. 1985 Jul;42(1):83–94. [PubMed]
  • Carroll MJ, Lister CA, Sennitt MV, Stewart-Long N, Cawthorne MA. Improved glycemic control in C57Bl/KsJ (db/db) mice after treatment with the thermogenic beta-adrenoceptor agonist, BRL 26830. Diabetes. 1985 Nov;34(11):1198–1204. [PubMed]
  • Danforth E, Jr, Horton ES, O'Connell M, Sims EA, Burger AG, Ingbar SH, Braverman L, Vagenakis AG. Dietary-induced alterations in thyroid hormone metabolism during overnutrition. J Clin Invest. 1979 Nov;64(5):1336–1347. [PMC free article] [PubMed]
  • Jung RT, Shetty PS, James WP. The effect of refeeding after semistarvation on catecholamine and thyroid metabolism. Int J Obes. 1980;4(2):95–100. [PubMed]
  • Cunningham S, Leslie P, Hopwood D, Illingworth P, Jung RT, Nicholls DG, Peden N, Rafael J, Rial E. The characterization and energetic potential of brown adipose tissue in man. Clin Sci (Lond) 1985 Sep;69(3):343–348. [PubMed]

Articles from British Medical Journal (Clinical Research Ed.) are provided here courtesy of BMJ Publishing Group